Is EMBT or EQR a better dividend investment in 2026?

EMBT currently yields 2000000.06% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: EMBT offers higher current income.

What is the dividend yield difference between EMBT and EQR?

EMBT has a forward dividend yield of 2000000.06% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 1999995.33 percentage points.

Home › Compare › EMBT vs EQR

EMBT vs EQR: Dividend Comparison 2026

EMBT yields 2000000.06% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EMBT wins by $4.8792278646347776e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EMBT

● Live price

2000000.06%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.8792278646347776e+39M

Annual income

$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00

Full EMBT calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — EMBT vs EQR

📍 EMBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EMBT	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EMBT + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EMBT pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMBT

Annual income on $10K today (after 15% tax)

$170,000,005.10/yr

After 10yr DRIP, annual income (after tax)

$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, EMBT beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMBT + EQR for your $10,000?

EMBT: 50%EQR: 50%

100% EQR50/50100% EMBT

Portfolio after 10yr

$2.4396139323173888e+39M

Annual income

$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EMBT

No analyst data

Altman Z

-1935.4

Piotroski

1/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMBT buys

EQR buys

No recent congressional trades found for EMBT or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEMBTEQR

Forward yield	2000000.06% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$4.8792278646347776e+39M	$40.5K ✓
Annual income after 10y	$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00 ✓	$3,819.61
Total dividends collected	$4.8791964691115763e+39M	$16.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: EMBT vs EQR ($10,000, DRIP)

Year	EMBT Portfolio	EMBT Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$200,010,706	$200,000,006.00	$11,248	$547.57	+$200.00M → EMBT
2	$3,738,731,992,770	$3,738,517,981,314.42	$12,701	$666.53	+$3738731.98M → EMBT
3	$65,315,068,744,949,500	$65,311,068,301,717,240.00	$14,405	$814.59	+$65315068744.94M → EMBT
4	$1,066,400,958,023,135,400,000	$1,066,331,070,899,578,300,000.00	$16,413	$999.84	+$1066400958023135.38M → EMBT
5	$16,272,185,237,131,282,000,000,000	$16,271,044,188,106,197,000,000,000.00	$18,795	$1,232.92	+$16272185237131282432.00M → EMBT
6	$232,054,281,880,765,440,000,000,000,000	$232,036,870,642,561,700,000,000,000,000.00	$21,639	$1,527.95	+$2.3205428188076545e+23M → EMBT
7	$3,092,799,715,549,616,000,000,000,000,000,000	$3,092,551,417,468,003,600,000,000,000,000,000.00	$25,057	$1,903.80	+$3.0927997155496157e+27M → EMBT
8	$38,524,114,942,504,994,000,000,000,000,000,000,000	$38,520,805,646,809,356,000,000,000,000,000,000,000.00	$29,197	$2,385.87	+$3.8524114942504996e+31M → EMBT
9	$448,468,947,092,778,960,000,000,000,000,000,000,000,000	$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00	$34,250	$3,008.70	+$4.4846894709277894e+35M → EMBT
10	$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000	$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00	$40,467	$3,819.61	+$4.8792278646347776e+39M → EMBT

EMBT vs EQR: Complete Analysis 2026

EMBT — Stock

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.

Full EMBT Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this EMBT vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMBT vs SCHD EMBT vs JEPI EMBT vs O EMBT vs KO EMBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.